Page 119 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer

Noise-induced variability of 89Zr-immuno-PET
a No brain VOI obtained in patient 2 (outside field of view) and 6 (tumor localization in the nasopharynx). b No brain VOI obtained in patient 6 (tumor localization in the nasopharynx).
c No kidney, lung, spleen, liver, blood pool, bone marrow in patient 2 (outside field of view). No brain VOI obtained in patient 6 (tumor localization in the nasopharynx). No brain VOI obtained in patient 1 (mismatch between low dose CT and PET image due to patient movement).
d No brain VOI obtained in patient 8 (outside field of view).
Supplemental Table 3 Mean differences (%) for normal tissue
and tumor uptake of Zr-89-mAbs
Brain Kidney Lung Spleen Liver Combined
Blood pool Bone marrow
Tumor
SUVmax SUVpeak SUVmean
89Zr-antiCD20
37 MBq74inj 18 MBq74inj
D0 D3 D6 D0 D3 n=7 n=6 n=6 n=7 n=6
-1.5 2.4 0.3 0.3 2.0 0.1 -1.5 -2.7 -0.1 0.4 0.2 -0.1 0.2 0.2 0.0 0.2 0.0 -0.6 0.0 2.7 -0.1 0.2 0.6 -0.1 -0.8 -0.2 0.1 -0.6 0.0 0.9
0.4 0.9 -12.7 0.4 6.8 -5.7 3.4 1.6 -8.5 -7.0
- D3 D6 - D3 n=26 n=32 n=26
- -4.1 0.3 - -5.0 - -4.9 0.4 - -4.7 - -6.5 0.3 - -1.0
89Zr-antiEGFR 18 MBq37inj
D6 D0 D3 D6 n=6 n=6 n=6 n=6
-2.9 0.8 -0.6 0.9 1.3 -1.8 1.5 -0.8 0.5 -0.2 0.3 -0.5 -8.3 2.1 2.3 -2.4 -0.9 0.7 0.2 -0.4 -1.7 0.3 0.7 -0.7
-6.3 4.3 -3.1 -2.1 13.9 -2.3 -0.1 6.3
D6 - D3 D6 n=32 n=7 n=7
1.7 - 9.5 1.3 2.0 - 9.4 4.5 2.7 - 5.6 2.1
89Zr-antiCD44 18 MBq37inj
D0 D1 D4 n=12 n=12 n=12
-1.3 0.6 0.5 0.2 0.4 -0.6 0.1 -0.1 1.4 0.0 -0.4 0.8 0.7 0.0 0.0 -0.1 0.1 0.4
-2.9 2.3 0.5 5 0.3 -0.9 -5.5
- D1 D4 n=19 n=19
- -3.0 -4.8 - -2.6 -3.5 - -1.3 -2.3
117